Actively Recruiting
Association Between Peri-procedural Intravenous Hydration and Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis
Led by University of Calgary · Updated on 2026-04-29
13000
Participants Needed
1
Research Sites
25 weeks
Total Duration
On this page
Sponsors
U
University of Calgary
Lead Sponsor
M
McGill University
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are studying the relationship between the amount of intravenous fluids given around the time of endoscopic retrograde cholangiopancreatography (ERCP) and the risk of developing post-ERCP pancreatitis (PEP). ERCP is a procedure with a relatively high risk of adverse events, especially pancreatitis, which causes significant healthcare costs and patient burden. This study aims to understand whether the amount of fluid given during the procedure affects the chance of developing PEP. The study compares two groups of patients based on the volume of intravenous crystalloid fluids they receive immediately before, during, and after ERCP. One group receives aggressive hydration with 2 liters or more of fluid, while the other group receives conservative hydration with less than 1 liter. The study uses data from a previous multicenter prospective cohort to analyze these differences. Participants are adults referred for ERCP who can provide informed consent. Researchers will evaluate the occurrence of PEP within 30 days as the primary outcome. Additional information collected includes procedure details and other adverse events. Statistical methods will be used to assess the relationship between fluid volume and PEP risk. The study will monitor patients for 30 days after ERCP to measure outcomes and gather data on procedure success and adverse events.
CONDITIONS
Brief Title
IV Fluids and Post-ERCP Pancreatitis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Subject referred for ERCP, regardless of indication
- Subject age 18 years or older
- Subject able to give informed consent to involvement be included
You will not qualify if you...
- Subject has a standard contraindication to ERCP
- Subject or surrogate unable or unwilling to provide informed consent
- Subject age < 18 years
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Immediate pre-, peri-, and post-procedural period
Participants undergo endoscopic retrograde cholangiopancreatography (ERCP) during which intravenous fluids are administered and various clinical data are collected.
1 procedure visit (in-person)
Duration - Up to 30 days after ERCP
Participants are monitored for post-ERCP pancreatitis and other adverse events following the procedure.
Follow-up visits or assessments up to 30 days
Trial Site Locations
Total: 1 location
1
Peter Lougheed Hospital
Calgary, Alberta, Canada
Actively Recruiting
Research Team
N
Nauzer Forbes, MD MSc
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here